Management of Chronic Pre-existing or Treatment-emergent Adverse Events of the “other" Systemic Therapies - Michael J. Morris

Michael Morris, Memorial Sloan Kettering Cancer Center, New York, US, focuses this discussion on prostate cancer specific aspects of side effects and how we can select the treatments, how to give them in which clinical states, to which patients, at what dose and at what intensity and for what duration.   Chemotherapy with docetaxel and cabazitaxel in both mCRPC and mCSPC (non-castrate) is presented along with exzalutamide and abiraterone acetate in the prechemotherapy and post chemotherapy settings.  (Presentation in 16 minutes).

View the slides

Bio-sketch:
Michael Morris is a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those who have metastatic disease (disease that has spread to distant organs) or who are at high risk of developing metastatic disease.

Much of his research bridges the fields of medical oncology and nuclear medicine. He is working with colleagues on Memorial Sloan Kettering’s Nuclear Medicine Service to develop radiopharmaceuticals  that deliver radiation therapy directly to cancer cells or to the areas in the skeleton that harbor prostate cancer cells. He is exploring one class of these drugs, called bone-seeking radiopharmaceuticals, in combination with chemotherapy. He is also exploring a new form of bone-seeking radiopharmaceutical that has fewer side effects in the bone marrow.

Another research interest is developing new ways to image prostate cancer in the bones using unique, prostate-cancer-specific PET scans and other new imaging modalities. This type of imaging not only provides an insight into where the prostate cancer is located, but informs about its biology as well.

Finally, he is interested in finding ways to prevent metastatic disease in patients who have undergone prostatectomy but whose PSA is rising rapidly. He is leading an international study for these patients in which they hope to determine whether early and aggressive treatment can delay, if not prevent, the development of metastases.

One of his priorities is increasing patient access to clinical trials. He is currently involved in the development of the Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. He also sits on Cancer and Leukemia Group B (CALGB)’s genitourinary committee, a National Cancer Institute-designated group composed of local and academic oncology centers, to facilitate clinical testing of new drugs throughout the country. In addition, he is involved with the American Society of Clinical Oncology (ASCO); He is on ASCO’s Education Committee and he chairs the Genitourinary Scientific Track.

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer